dean fennell
University of Leicester
H-index: 61
Europe-United Kingdom
Top articles of dean fennell
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
First-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 triggers mesenchymal-to-epithelial transition in mesothelioma | Cancer Research | Terri Messier Victoria Gibson David J Seward Essa Y Baitei Peter Wells Jordan | 2024/3/22 |
ASTX295 engages p53-mediated apoptosis and an inflammatory response in patient derived mesothelioma explants | Cancer Research | Dean Anthony Fennell Joanna Dzialo Jan Rogel Daniel Faulkner Nada Nusrat | 2024/3/22 |
208 SynthEtic LEthal Cancer Therapy in mesothelioma (SELECTmeso): a molecularly stratified multi-arm phase II platform trial for patients with relapsed malignant mesothelioma | Lung Cancer | Kayleigh Hill Dean Fennell Anna Song Robin Wickens Judith Cave | 2024/4/1 |
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the ‘T’Descriptors in the Forthcoming 9th Edition of the TNM Classification for Pleural Mesothelioma | Journal of thoracic oncology | Anna K Nowak Kari Chansky David C Rice Harvey I Pass Hedy L Kindler | 2016/12/1 |
61 The first-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 modulates the mesenchymal and immune phenotype in mesothelioma | Lung Cancer | Brian Cunniff Terri Messier Victoria Gibson David Seward Essa Baitei | 2024/4/1 |
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial | JAMA oncology | Peter W Szlosarek Benjamin C Creelan Thomas Sarkodie Luke Nolan Paul Taylor | 2024/2/15 |
The IASLC Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor after Resection for the Forthcoming (9th) Edition of the TNM … | William D Travis Hisao Asamura Alexander A Bankier Mary Beth Beasley Frank Detterbeck | 2016/8/1 | |
Gene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways | Genes, Chromosomes and Cancer | Maymun Jama Min Zhang Charlotte Poile Apostolos Nakas Annabel Sharkey | 2024/1 |
SLC7A11 modulates sensitivity to the first-in-class mitochondrial peroxiredoxin 3 inhibitor thiostrepton (RSO-021) via a ferroptosis independent pathway | Cancer Research | Terri Messier Victoria Gibson Aleksandra Bzura Joanna Dzialo Charlotte Poile | 2024/3/22 |
Effects of RSO-021 on cytokine profiles of malignant pleural effusions from patients enrolled in the MITOPE phase 1/2 clinical trial | Terri Messier Molly Scotland George Naumov Sean Dulloo Dean Fennell | 2023/12/1 | |
The evolution of lung cancer and impact of subclonal selection in TRACERx | Nature | Charles Swanton Nicholas McGranahan Mariam Jamal-Hanjani Alexander M Frankell Michelle Dietzen | 2023/4/20 |
Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma. | Dean Anthony Fennell Sean Ewings Kayleigh Hill Charlotte Poile Essa Baitei | 2023/6/1 | |
BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms | Oncogene | Anita Singh Sara Busacca Aarti Gaba Michael Sheaff Charlotte Poile | 2023/2/17 |
OA02. 05 Dendritic Cell Immunotherapy Versus Best Supportive Care as Maintenance Treatment in Patients with Pleural Mesothelioma | Journal of Thoracic Oncology | JGJV Aerts B Belderbos P Baas A Scherpereel R Berardi | 2023/11/1 |
Abstract C027: RSO-021, a first-in-class covalent inhibitor of mitochondrial PRX3: From bench to bedside | Dean A Fennell Sean Dulloo Peter Szlosarek Fiona Thistlethwaite Simon Lord | 2023/12/1 | |
Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy. | Matthew G Krebs Amy Branson Shaun Barber Charlotte Poile Amy King | 2023/6/1 | |
The evolution of non-small cell lung cancer metastases in TRACERx | Nature | Maise Al Bakir Ariana Huebner Carlos Martínez-Ruiz Kristiana Grigoriadis Thomas BK Watkins | 2023/4/20 |
Protocol: Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm … | BMJ Open | Dean Fennell Daniel Griffiths Zina Eminton Abigail Morgan-Fox Kayleigh Hill | 2023 |
P2. 18-02 Successful Generation of Tumor-Infiltrating Lymphocytes (TIL) for Adoptive Cell Therapy from Mesothelioma | Journal of Thoracic Oncology | DA Fennell C Poile A Bzura J Dzialo A Nakas | 2023/11/1 |
Abstract B022: Effects of RSO-021 on cytokine profiles of malignant pleural effusions from patients enrolled in the MITOPE phase 1/2 clinical trial | Molecular Cancer Therapeutics | Terri Messier Molly Scotland George Naumov Sean Dulloo Dean Fennell | 2023/12/1 |
